Status:
COMPLETED
A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia
Lead Sponsor:
Sumitomo Pharma America, Inc.
Conditions:
Schizophrenia
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
Brief Summary
A 6-week in-patient and out-patient study to test the effectiveness and safety of a new medication in the treatment of schizophrenia
Detailed Description
Study will evaluate the efficacy of a new compound versus placebo in the treatment of patients with schizophrenia (diagnosed by DSM-IV criteria) as measured by reductions from baseline on the total sc...
Eligibility Criteria
Inclusion
- Satisfy DSM-IV criteria for schizophrenia as established by SCID-CV
- The patient must agree to a voluntary hospitalization duration of 31 days minimum at the start of the treatment
- If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception
Exclusion
- The patient has used an investigational drug within the past 30 days
- The patient has participated in a previous study of this compound
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2004
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00088634
Start Date
May 1 2004
End Date
December 1 2004
Last Update
April 8 2016
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham Psychiatry Pharmaceutical
Birmingham, Alabama, United States, 35209
2
Summit Research Group
Little Rock, Arkansas, United States, 72211
3
Comprehensive NeuroScience
Cerritos, California, United States, 90703
4
Collaborative Neuro Science Network, Inc.
Garden Grove, California, United States, 92845